Approvals were down slightly year over year.
News & Analysis: Mylan
Mylan’s planned combination with Upjohn is a bright spot for investors, but the difficulties of the U.S. generic-drug market remain a potential obstacle.
It was a trying year for the generic drug manufacturer. Can a combination with Pfizer help to soothe beleaguered investors?
The idea is among a set of proposals aimed at cooling healthcare costs in the state.
Trace amounts of carcinogens were found in Mylan's nizatidine capsules.
MYL earnings call for the period ending September 30, 2019.
A settlement in a closely watched Ohio case averted a federal trial and paves the way to a nationwide settlement -- if drug companies shorten their payment timelines.
Mylan plans to merge with a spinoff from Pfizer, and Merck had more good news about its blockbuster cancer drug.
The drugmaker's revenue improved in the second quarter with new product launches, but higher spending weighed on its earnings.
A proposed combination with Pfizer's Upjohn unit is exciting Mylan shareholders.